Literature DB >> 28433458

Linking the biological underpinnings of depression: Role of mitochondria interactions with melatonin, inflammation, sirtuins, tryptophan catabolites, DNA repair and oxidative and nitrosative stress, with consequences for classification and cognition.

George Anderson1.   

Abstract

The pathophysiological underpinnings of neuroprogressive processes in recurrent major depressive disorder (rMDD) are reviewed. A wide array of biochemical processes underlie MDD presentations and their shift to a recurrent, neuroprogressive course, including: increased immune-inflammation, tryptophan catabolites (TRYCATs), mitochondrial dysfunction, aryl hydrocarbonn receptor activation, and oxidative and nitrosative stress (O&NS), as well as decreased sirtuins and melatonergic pathway activity. These biochemical changes may have their roots in central, systemic and/or peripheral sites, including in the gut, as well as in developmental processes, such as prenatal stressors and breastfeeding consequences. Consequently, conceptualizations of MDD have dramatically moved from simple psychological and central biochemical models, such as lowered brain serotonin, to a conceptualization that incorporates whole body processes over a lifespan developmental timescale. However, important hubs are proposed, including the gut-brain axis, and mitochondrial functioning, which may provide achievable common treatment targets despite considerable inter-individual variability in biochemical changes. This provides a more realistic model of the complexity of MDD and the pathophysiological processes that underpin the shift to rMDD and consequent cognitive deficits. Such accumulating data on the pathophysiological processes underpinning MDD highlights the need in psychiatry to shift to a classification system that is based on biochemical processes, rather than subjective phenomenology.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aryl hydrocarbon; Classification; Cognition; Immune-inflammation; Kynurenine; Major depressive disorder; Melatonin; Mitochondria; Oxidative and nitrosative stress; Pathophysiology; Treatment

Mesh:

Substances:

Year:  2017        PMID: 28433458     DOI: 10.1016/j.pnpbp.2017.04.022

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  23 in total

Review 1.  Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target.

Authors:  W Swardfager; M Hennebelle; D Yu; B D Hammock; A J Levitt; K Hashimoto; A Y Taha
Journal:  Neurosci Biobehav Rev       Date:  2018-02-02       Impact factor: 8.989

Review 2.  The role of tryptophan metabolism in postpartum depression.

Authors:  Kai-Ming Duan; Jia-Hui Ma; Sai-Ying Wang; ZhengDong Huang; YingYong Zhou; HeYa Yu
Journal:  Metab Brain Dis       Date:  2018-01-06       Impact factor: 3.584

Review 3.  Circadian modulation of neuroplasticity by melatonin: a target in the treatment of depression.

Authors:  Marcela Valdés-Tovar; Rosa Estrada-Reyes; Héctor Solís-Chagoyán; Jesús Argueta; Ana María Dorantes-Barrón; Daniel Quero-Chávez; Ricardo Cruz-Garduño; Montserrat G Cercós; Citlali Trueta; Julián Oikawa-Sala; Margarita L Dubocovich; Gloria Benítez-King
Journal:  Br J Pharmacol       Date:  2018-04-17       Impact factor: 8.739

4.  Identification of Genetic Variations in the NAD-Related Pathways for Patients with Major Depressive Disorder: A Case-Control Study in Taiwan.

Authors:  Daniel Tzu-Li Chen; Szu-Wei Cheng; Tiffany Chen; Jane Pei-Chen Chang; Bing-Fang Hwang; Hen-Hong Chang; Eric Y Chuang; Che-Hong Chen; Kuan-Pin Su
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

Review 5.  Reciprocal Interactions of Mitochondria and the Neuroimmunoendocrine System in Neurodegenerative Disorders: An Important Role for Melatonin Regulation.

Authors:  Victoria O Polyakova; Igor M Kvetnoy; George Anderson; Jessica Rosati; Gianluigi Mazzoccoli; Natalya S Linkova
Journal:  Front Physiol       Date:  2018-03-12       Impact factor: 4.566

Review 6.  Mitochondria and Mood: Mitochondrial Dysfunction as a Key Player in the Manifestation of Depression.

Authors:  Josh Allen; Raquel Romay-Tallon; Kyle J Brymer; Hector J Caruncho; Lisa E Kalynchuk
Journal:  Front Neurosci       Date:  2018-06-06       Impact factor: 4.677

7.  A Critical Role of Mitochondria in BDNF-Associated Synaptic Plasticity After One-Week Vortioxetine Treatment.

Authors:  Fenghua Chen; Jibrin Danladi; Maryam Ardalan; Betina Elfving; Heidi K Müller; Gregers Wegener; Connie Sanchez; Jens R Nyengaard
Journal:  Int J Neuropsychopharmacol       Date:  2018-06-01       Impact factor: 5.176

Review 8.  Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing.

Authors:  Zhiqiang Ma; Liqun Xu; Dong Liu; Xiaoyan Zhang; Shouyin Di; Weimiao Li; Jiao Zhang; Russel J Reiter; Jing Han; Xiaofei Li; Xiaolong Yan
Journal:  Oxid Med Cell Longev       Date:  2020-05-21       Impact factor: 6.543

Review 9.  Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders.

Authors:  Lindsay M Melhuish Beaupre; Gregory M Brown; Vanessa F Gonçalves; James L Kennedy
Journal:  Transl Psychiatry       Date:  2021-06-02       Impact factor: 6.222

10.  Circulating cell-free mitochondrial DNA, but not leukocyte mitochondrial DNA copy number, is elevated in major depressive disorder.

Authors:  Daniel Lindqvist; Owen M Wolkowitz; Martin Picard; Lars Ohlsson; Francesco S Bersani; Johan Fernström; Åsa Westrin; Christina M Hough; Jue Lin; Victor I Reus; Elissa S Epel; Synthia H Mellon
Journal:  Neuropsychopharmacology       Date:  2018-01-30       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.